BMS Korea's myelofibrosis drug Inrebic will be covered from June. This drug is expected as a second-line treatment option for myelofibrosis patients, of which there are about 1,700 in Korea.

According to the industry on the 19th, Inrebic will be listed as a salary at 39,520 won per capsule for the maximum amount from June 1st. Inrevic Capsule is indicated for the treatment of splenomegaly or symptoms associated with the following diseases in adult patients previously treated with Ruxolitinib (Brand Name: Jakavi). The following diseases are ▲primary myelofibrosis, ▲myelofibrosis after polycythemia vera, ▲and myelofibrosis after essential thrombocythemia.

In February, it passed the HIRA